Overview

Schizotypal Personality Disorder Risperidone

Status:
Completed

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

Neurophysiological indices of self-monitoring were assessed in a group of patients with Schizotypal Personality Disorder (SPD) and a control group. Both groups were assessed after the administration of risperidone and placebo.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Treatments:

Risperidone